Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03738475 · ClinicalTrials.gov registry record · Phase 2
Study of the Safety, Pharmacodynamics, Efficacy, and PK of TIMP-GLIA in Subjects With Celiac Disease
A Phase 2 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT03738475 is a Phase 2 study that has completed, run by Takeda. The registered enrollment target is 34 participants.
The verdict
NCT03738475, a Phase 2 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
Subjects enrolled in this study will be evaluated for immune responses and histological changes in the small bowel following 2 doses of TIMP-GLIA or placebo and a 14-day oral gluten challenge.
Interventions
- DRUG Placebo
- DRUG TIMP-GLIA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2018-11-11 |
| Est. Completion | 2019-07-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03738475
The ClinicalTrials.gov registry entry for NCT03738475 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03738475 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03738475 about?
NCT03738475 is a clinical study titled "Study of the Safety, Pharmacodynamics, Efficacy, and PK of TIMP-GLIA in Subjects With Celiac Disease". Subjects enrolled in this study will be evaluated for immune responses and histological changes in the small bowel following 2 doses of TIMP-GLIA or placebo and a 14-day oral gluten challenge.
What is the current status of trial NCT03738475?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2018-11-11. Estimated completion is 2019-07-22.
What interventions are being tested in trial NCT03738475?
The interventions under investigation include: Placebo (DRUG), TIMP-GLIA (DRUG).
Who is sponsoring clinical trial NCT03738475?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.